MARKET

RYTM

RYTM

Rhythm Pharmaceu
NASDAQ
43.33
+1.54
+3.69%
After Hours: 43.33 0 0.00% 19:58 03/28 EDT
OPEN
42.54
PREV CLOSE
41.79
HIGH
43.66
LOW
41.79
VOLUME
876.12K
TURNOVER
0
52 WEEK HIGH
52.57
52 WEEK LOW
15.50
MARKET CAP
2.61B
P/E (TTM)
-13.5313
1D
5D
1M
3M
1Y
5Y
Viking Therapeutics gains on early data for oral weight loss therapy
Seeking Alpha · 2d ago
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
3 analysts have maintained Buy ratings on Rhythm Pharmaceuticals, Beam Therapeutics and Glaukos. The 3 stocks are in the Healthcare sector. Analyst consensus on Glau Kos is a Strong Buy with an average price target of $105.13. 3 analysts have recently weighed in on the 3 stocks with bullish sentiments.
TipRanks · 3d ago
Weekly Report: what happened at RYTM last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at RYTM last week (0311-0315)?
Weekly Report · 03/18 09:35
Weekly Report: what happened at RYTM last week (0304-0308)?
Weekly Report · 03/11 09:34
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
Weekly Report: what happened at RYTM last week (0226-0301)?
Weekly Report · 03/04 09:35
Weekly Report: what happened at RYTM last week (0219-0223)?
Weekly Report · 02/26 09:38
More
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

Webull offers Rhythm Pharmaceuticals Inc stock information, including NASDAQ: RYTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RYTM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RYTM stock methods without spending real money on the virtual paper trading platform.